Study of Clinical Non-inferiority of Actparin® (Laboratorio Bergamo) Compared to Heparin Sodium (APP Pharmaceuticals), in Patients With Chronic Renal Failure

Inclusion Criteria: * Patients research that agree to participate in the study and sign the informed consent form; * Patients aged over 18 years, both sexes, regardless of color or social class; * Patients with impaired renal function in chronic hemodialysis schedule of at least 3 times a week and giving the use of heparin in the prophylaxis of thrombosis in the system; * Patients with laboratory results within specified acceptance criteria. Exclusion Criteria: * Patients who are taking part or took part in another clinical investigational study within 12 months; * Hypersensitivity to heparin sodium and/or benzyl alcohol; * History of active hemorrhage with alteration of blood coagulation, such as genetic disorders of coagulation system; * History of disease that could aggravate or terminate the clinical manifestations, such as active peptic or gastric ulcer; * Severe liver disease; * Patients in cancer treatment; * Pregnant and lactating women; * Use of glucocorticoids over physiological dose; * Use of other anticoagulants; * Patients undergoing any surgery performed less than 15 days; * History of non response or exacerbated response to heparin sodium; * Patients who do not adapt to 150 UI/kg dose.